Quest Diagnostics Inc

DGX remains in a constructive long- and medium-term uptrend but is experiencing a short-term pullback below the 9-day and 20-day EMAs into the 50-day SMA support. RSI is approaching oversold territory while the 50-day SMA held on the last pullback, indicating potential stabilization without a clear reversal yet. The medium-term bias remains bullish, but short-term execution is unfavorable—defer entries and stalk for a reclaim of the EMA zone or acceptance at the 50-day SMA support.

• ↑Q2 2026 revenue $3.04 B (+10.2% YoY)
• ↑FY 2026 revenue guidance up to $11.95–12.05 B (≈8.3–9.2% growth)
• ↓Potential PAMA payment cuts threaten 2027 revenues and margins